Peptide record

TPDB11544

Antibacterial Anticancer Antifungal Antiparasitic standard
34 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB11544
Antibacterial Anticancer Antifungal Antiparasitic
Anti-infective peptides Cancer-related peptides
AntiBP3 pep-lab Peptipedia AntiCP 2.0 iACP-DRLF Antifungipept i2APP
standard
No
A 34-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, pep-lab, Peptipedia, and other sources, with an available 3D structural model.
Sequence
GRCVCRKQLLCSYRERRIGDCKIRGVRFPFCCPR
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C172H289N61O42S6
ANHMTW
R
4075.93
10.21
10
2
9
+8
3.26
-0.447
62.94
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
1865
0.46
9
Residue Composition
number
0
A
8
R
0
N
1
D
6
C
1
E
1
Q
3
G
0
H
2
I
2
L
2
K
0
M
2
F
2
P
1
S
0
T
0
W
1
Y
2
V
Amino Acid Distribution
A: 0 R: 8 N: 0 D: 1 C: 6 E: 1 Q: 1 G: 3 H: 0 I: 2 L: 2 K: 2 M: 0 F: 2 P: 2 S: 1 T: 0 W: 0 Y: 1 V: 2
Chemical Descriptors
34 reviewed residue count
C172H289N61O42S6 sequence-only estimate (linear, free termini)
4075.93 sequence-only estimate (linear, free termini)
10.21 sequence-only estimate (linear, free termini)
+8 sequence-only estimate (linear, free termini)
3.26 sequence-only estimate (linear, free termini)
-0.447 sequence-only estimate (linear, free termini)
Evidence Records 3 records
Evidence 1 Activity

Activity

Antibacterial

Source & Reference

NA

Other

log deduction after 20 min incubation with 50 ug/ml peptide. Active against S. aureus strains 566, 502A, J.F. (reduction 0.3-1.7 logs), S. epidermidis UCLA-622 (reduction 1.7 logs), S. pneumoniae Type III (reduction >3.5 log), S. agalactiae Type I-A or III (reduction 0.9-1.2 logs), L. monocytogenes 450 (reduction 4.3 logs), P. aeruginosa PAO579 (reduction 4.2 logs), E. coli ATCC 29648 (reduction 1.4 logs), K. pneumoniae ATCC 13883 (reduction 3.4 logs), S. marcescens (reduction 0.7 log), H. influenzae Type 3A (reduction 0.7 log), B. bronchiseptica UCLA-342 (reduction 0.1 log).
Evidence 2 Activity

Activity

Antifungal

Source & Reference

Antifungipept

Other

log deduction after 20 min incubation with 50 ug/ml peptide. Active against S. aureus strains 566, 502A, J.F. (reduction 0.3-1.7 logs), S. epidermidis UCLA-622 (reduction 1.7 logs), S. pneumoniae Type III (reduction >3.5 log), S. agalactiae Type I-A or III (reduction 0.9-1.2 logs), L. monocytogenes 450 (reduction 4.3 logs), P. aeruginosa PAO579 (reduction 4.2 logs), E. coli ATCC 29648 (reduction 1.4 logs), K. pneumoniae ATCC 13883 (reduction 3.4 logs), S. marcescens (reduction 0.7 log), H. influenzae Type 3A (reduction 0.7 log), B. bronchiseptica UCLA-342 (reduction 0.1 log).
Evidence 3 Activity

Activity

Antiparasitic

Source & Reference

NA

Other

log deduction after 20 min incubation with 50 ug/ml peptide. Active against S. aureus strains 566, 502A, J.F. (reduction 0.3-1.7 logs), S. epidermidis UCLA-622 (reduction 1.7 logs), S. pneumoniae Type III (reduction >3.5 log), S. agalactiae Type I-A or III (reduction 0.9-1.2 logs), L. monocytogenes 450 (reduction 4.3 logs), P. aeruginosa PAO579 (reduction 4.2 logs), E. coli ATCC 29648 (reduction 1.4 logs), K. pneumoniae ATCC 13883 (reduction 3.4 logs), S. marcescens (reduction 0.7 log), H. influenzae Type 3A (reduction 0.7 log), B. bronchiseptica UCLA-342 (reduction 0.1 log).